The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Final results of phase I/II trial of vorinostat in combination with cyclophosphamide, etoposide, prednisone, and rituximab (R-CVEP) for elderly patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
David J. Straus
Research Funding - Merck
Paul A. Hamlin
Research Funding - Merck
Matthew J. Matasar
No relevant relationships to disclose
Maria Lia Palomba
No relevant relationships to disclose
Pamela Drullinsky
No relevant relationships to disclose
Andrew David Zelenetz
No relevant relationships to disclose
John F. Gerecitano
No relevant relationships to disclose
Ariela Noy
No relevant relationships to disclose
Audrey M. Hamilton
No relevant relationships to disclose
Brett Wegner
Research Funding - Merck
Zhigang Zhang
Research Funding - Merck
Rebecca L. Elstrom
Research Funding - Merck
David Cella
Research Funding - Merck